Communiqués Fate Therapeutics, Inc.

Actions

FATE

US31189P1021

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 04/08/2026			Varia. 5j.	Varia. 1 janv.
2,570 ^USD	+2,80%		+10,78%	+161,55%

09/07	L'action Fate Therapeutics progresse après le feu vert de la FDA pour la demande de nouveau médicament expérimental du FT839	MT
09/07	Fate Therapeutics reçoit le feu vert de la FDA pour sa demande de nouveau médicament expérimental concernant le candidat-produit FT839	CI

Communiqués

04/08	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - August 3, 2026	AQ
03/08	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	GL
09/07	Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate	GL
06/07	Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting	GL
01/07	Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences	GL
15/06	Fate Therapeutics Appoints Laura Hamill to Board of Directors	GL
04/06	Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting	GL
02/06	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	GL
01/06	Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting	GL
21/05	Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases	GL
13/05	Fate Therapeutics: Q1 Earnings Snapshot	AQ
13/05	Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates	GL
11/05	Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting	GL
05/05	Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819	GL
04/05	Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	AQ
04/05	Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases	GL
04/05	Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases	AQ
01/05	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	GL
30/04	Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting	GL
17/04	Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases	AQ
16/04	Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting	GL
09/04	Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences	GL
02/04	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	GL
18/03	The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed	AQ
04/03	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	GL